NCT00109200View on ClinicalTrials.gov

A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2003

Study Completion Date

September 30, 2003

Conditions
Asthma
Interventions
DRUG

Xolair (omalizumab)

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY